Back to search

University of Alabama Birmingham

A Comparison of Growth Factor Release Between Platelet Rich fibrin and Recombinant Human Platelet Derived Growth Factor BB (RHPDGF-BB) and Beta-Tricalcium Phosphate: An In Vitro Analysis

Abstract

dc:description.abstract

Patients presenting with significant alveolar bone loss can pose challenges for the clinician. Traditional bone augmentation techniques may be inadequate in achieving necessary gains to restore missing teeth with dental implants. The adjunctive use of growth factors may accelerate the healing process and enhance tissue regeneration. GEM21S is a product that includes a recombinant growth factor approved by the Federal Drug Administration for oral surgery. It is delivered as a two-component system: 1) recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and 2) betatricalcium phosphate (β-TCP).[1] The research on GEM 21S for ridge augmentation is mostly limited to case studies.[2- 4] Biologically, PDGF-BB triggers chemotaxis and mitogenesis of cells of mesenchymal origin.[5,6] It also works synergistically with BMP-2 in bone formation.[7-9] These are ideal properties for wound and bone healing that should be investigated further for potential beneficial effects in ridge augmentation cases. Today, platelet-rich fibrin (PRF) is commonly used as an adjunctive measure in ridge augmentation. PRF is a second-generation autologous platelet concentrate that contains a supraphysiologic concentration of molecular mediators, including a variety of growth iv factors.[10] The concept of utilizing PRF to make a growth factor-enriched bone graft matrix (“sticky bone”) has been described. The addition of PRF has been noted to improve handling properties and volumetric stability of the bone graft. Further, due to its natural fibrin clot formation, PRF may provide a scaffold to allow more gradual release of growth factors during healing. Although the use of PRF in oral surgery has the potential to enhance wound healing, its utility may have limitations as PRF has been shown to resorb within a 2 to 3-week period and no osteoinductive capabilities of PRF have been demonstrated. The rationale for this study is that PDGF-BB is proven to play a critical role in wound healing. It is postulated that a combinatorial approach with PRF could provide clinicians the benefits of a clinically proven and consistent dose of rhPDGF-BB to improve wound healing and bone formation in conjunction with the benefits of the improved physical handling properties of PRF as well as the potential for a longer duration of growth factor delivery.

Degree

thesis:*
Level thesis:degree_level
Thesis

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Misch, Maggie Ann
Contributors dc:contributor
  • Maria Geisinger
  • Ramzi Abou-Arraj
  • Nico Geurs
  • Amjad Javed

Subjects

dc:subject × 1

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Alabama Birmingham
Base URL
digitalcommons.library.uab.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Misch, Maggie Ann. A Comparison of Growth Factor Release Between Platelet Rich fibrin and Recombinant Human Platelet Derived Growth Factor BB (RHPDGF-BB) and Beta-Tricalcium Phosphate: An In Vitro Analysis. Thesis thesis, https://digitalcommons.library.uab.edu/etd-collection/571